Phase II Results for Niraparib in Heavily Pretreated Patients With Ovarian Cancer
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses results from the phase II open-label, single-arm QUADRA study evaluating niraparib in patients with relapsed ovarian cancer who have received ≥3 prior chemotherapy regimens during the 2018 ASCO Annual Meeting.
During the 2018 ASCO Annual Meeting, Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses results from the phase II open-label, single-arm QUADRA study evaluating niraparib (Zejula) in patients with relapsed ovarian cancer who have received ≥3 prior chemotherapy regimens.
There was a 29% response rate found with niraparib, which is a very exciting result in this heavily pretreated population, Matulonis says. In patients with heavily pretreated ovarian cancer with a germlineBRCAmutation, the response rate was over 40%, while patients with platinum-resistant ovarian cancer had a response rate of approximately 25%.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
